glp-1 science The revolution: What UAB researchers are discovering about how these drugs work GLP-1 Receptor Agonists | New

Prescribing & titration is anticipated to lead with 46.0% share in 2026

For best results, combine GLP1s with behavioral, dietary, and lifestyle changes

Eligibility generally requires a BMI of 30 or higher , or a BMI of 27+ with a weight-related condition such as high blood pressure, high cholesterol, prediabetes, or type 2 diabetes, in line with standard GLP-1 prescribing guidelines

Emerging Role of GLP-1 Receptor Agonists for the Treatment of MASH Abstract: Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes, and other metabolic disorders